SARomics Biostructures
- Company typePrivate
- Founded2006
- HeadquartersLund, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingServices
SARomics Biostructures firmographics
Firmographics- Name
- SARomics Biostructures
- Legal name
- SARomics Biostructures AB
- Website
- https://saromics.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
SARomics Biostructures industry classification
Industry- Product category
- Structural Biology Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
- akta.pro secondary industry
- Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)
Keywords
Where SARomics Biostructures is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices3 records
Markets served
SARomics Biostructures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Fee-for-service model with payments scheduled against specific project milestones. Includes initial startup fee and subsequent payments tied to project progress. FTE-based payments available upon agreement with customer.
- Structural Biology Services: Services include protein crystallization and structure determination, fragment screening, hit identification, and structure-based lead generation and optimization. Revenue generated through project-based contracts with pharmaceutical, biotech, and academic clients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Fee-for-service with milestone payments |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
SARomics Biostructures product offering
Product offeringCore offering
SARomics Biostructures is a contract research organization (CRO) that delivers fee-for-service structural biology and drug discovery projects for pharmaceutical, biotech, and academic clients. Its core services include protein X-ray crystallography, BioNMR spectroscopy, crystallographic and WAC™ fragment screening, antibody epitope mapping, higher-order structure (HOS) analysis, and structure-based lead optimization, supported by its FastLane™ protein catalog and priority access to the MAX IV synchrotron beamlines.
Product overview
SARomics Biostructures offers an integrated structural biology and drug discovery services platform combining X-ray crystallography, BioNMR spectroscopy, proprietary WAC™ fragment screening technology, and FastLane™ off-the-shelf protein catalogs. The platform enables gene-to-structure workflows, crystallographic fragment screening, NMR-based higher-order structure analysis, and DNA-encoded library screening (in partnership with Vipergen). Key offerings include custom protein structure determination, antibody epitope mapping, biosimilar comparability studies, and structure-based lead optimization services for biotech, pharmaceutical, and academic clients worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- X-ray Crystallography Services
Quantifiable outcome
- Over 100 structural biology and drug discovery projects completed annually
- +4 more outcomes
Companies that use SARomics Biostructures
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
SARomics Biostructures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
SARomics Biostructures partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major, core and minor.
- Accelero Biostructures Inc.majorStrategic collaboration announced April 2026 combining structural biology services including protein X-ray crystallography and structure-based drug discovery. Aims to streamline workflows, reduce redundancy, and expand service capabilities. SARomics brings 20 years of experience, Accelero brings 10+ years.
- Vipergen ApScoreStrategic partnership to offer enhanced hit and lead identification services combining Vipergen's DNA-encoded library (DEL) screening technologies with SARomics' structural biology capabilities. Vipergen's DEL screening can identify novel hits from over 500 million drug-like molecules, while SARomics provides detailed structural information including binding site mapping and binding poses.
- LundaGUARD ConsortiumminorConsortium to fight infectious agents including LP3 (Protein Production Platform at Lund University), MAX IV, ESS, and University College London. Leverages WAC-screening platform for COVID-19 drug discovery.
- Carna Biosciences Inc.majorExclusive distribution agreement covering Japanese market for SARomics services.
- Vectron BiosolutionsminorPartnership for customized gene-to-structure projects, utilizing Vectron's expertise in protein production and SARomics' expertise in protein crystallization and structure determination.
- Red Glead DiscoverycoreClose collaboration on integrated drug discovery projects including WAC fragment screening technology (jointly owned), gene-to-lead projects, and various pharmaceutical partnerships. Partners on EU projects including Virus-X, BIOCASCADES, and others.
- MAX IV LaboratorycorePartnership for FragMAX fragment screening platform and access to BioMax and MicroMax beamlines for X-ray crystallography. Located just kilometers from SARomics labs at Medicon Village.
- FragMAX Platform StaffcoreCollaboration on FragMAX platform for crystallographic fragment screening, including design of kinase-focused fragment library developed with Jens Carlsson, Szymon Pach, and Philip Ullmann from Uppsala University.
Scale indicators11 records
Recent moves8 records
Expansion highlights4 records
SARomics Biostructures competitors and assessment
Company assessmentDirect peers
- Proteros Biotechnologies: Munich-based structural biology CRO offering protein crystallography, fragment screening (Pioneer™), and structure-based drug discovery services to pharma and biotech. Closest direct competitor to SARomics with very similar service portfolio and target customer base.
- ZoBio: Dutch structural biology CRO specializing in protein crystallography, fragment screening by NMR and X-ray, and structure-based drug design. Highly comparable niche CRO competing for similar biotech and pharma accounts.
- Domainex: UK-based CRO offering integrated drug discovery including protein crystallography, fragment screening, and medicinal chemistry. Comparable niche CRO targeting similar biotech and pharma customers.
- Astex Pharmaceuticals: Fragment-based drug discovery specialist using X-ray crystallography and proprietary fragment libraries (e.g., Pyramid™). Direct overlap with SARomics' fragment screening and structure-based lead optimization services.
Broad incumbents
- Evotec SE: Large global CRO/CDMO with structural biology and fragment-based drug discovery capabilities embedded in a much broader service portfolio. Represents the scaled incumbent SARomics competes against for larger pharma contracts.
- Charles River Laboratories: Major CRO with extensive structural biology, protein sciences, and drug discovery offerings across a global footprint. Serves as the dominant scaled alternative for enterprises considering structural biology outsourcing.
- Schrödinger, Inc. Computational chemistry and structure-based drug design platform with growing wet-lab/biopharma collaborations. Adjacent and partially overlapping in the structure-based design value chain.
- WuXi AppTec: Massive global CRO/CDMO offering structural biology alongside a full suite of discovery, development, and manufacturing services. Represents a competitive threat on price, scale, and global account coverage.
Emerging players
- Vipergen ApS: Danish DNA-encoded library screening technology provider. SARomics' partner in DEL screening services; comparable as an emerging platform player intersecting with SARomics' hit identification pipeline.
Regional players
- Carna Biosciences: Japan-based kinase-focused drug discovery CRO and SARomics' exclusive Japanese distributor. Operates in adjacent kinase biology and serves as both a partner and a partial competitor in APAC structural biology services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
SARomics Biostructures social profiles
Digital presenceSARomics Biostructures financial estimates
Financial estimateRevenue estimate
Valuation estimate
SARomics Biostructures leadership team
Management profileNumber of profiles
Profiles2 records
SARomics Biostructures funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SARomics Biostructures M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SARomics Biostructures
What does SARomics Biostructures do?
SARomics Biostructures is a contract research organization (CRO) that delivers fee-for-service structural biology and drug discovery projects for pharmaceutical, biotech, and academic clients. Its core services include protein X-ray crystallography, BioNMR spectroscopy, crystallographic and WAC™ fragment screening, antibody epitope mapping, higher-order structure (HOS) analysis, and structure-based lead optimization, supported by its FastLane™ protein catalog and priority access to the MAX IV synchrotron beamlines.
Is SARomics Biostructures a public or private company?
SARomics Biostructures is a private company. It is classified as venture growth investor backed and is currently operating.
When was SARomics Biostructures founded?
SARomics Biostructures was founded in 2006. It employs 11 to 50 people.
Where is SARomics Biostructures based?
SARomics Biostructures is headquartered in Lund, Sweden, in the Europe region.
How does SARomics Biostructures make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are structural Biology Services.
Who are SARomics Biostructures's main competitors?
Direct peers on record are Proteros Biotechnologies, ZoBio, Domainex and Astex Pharmaceuticals. Broad incumbents are Evotec SE, Charles River Laboratories, Schrödinger, Inc. and WuXi AppTec. Vipergen ApS is listed as an emerging player. Carna Biosciences is listed as a regional player.
Does SARomics Biostructures have an API?
No public API is recorded for SARomics Biostructures.
What industry is SARomics Biostructures in?
SARomics Biostructures's product category is Structural Biology Contract Research Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 541714 and its SIC code is 8731.